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Targeting Pemphigus Autoantibodies through their
Heavy-Chain Variable Region Genes
Aimee S. Payne1, Don L. Siegel2 and John R. Stanley1
Pemphigus vulgaris (PV) is a potentially fatal blistering disease characterized by autoantibodies against cell
surface adhesion proteins desmoglein (Dsg) 3 and Dsg1. Previous studies using phage display to clone Dsg-
reactive monoclonal antibodies from a PV patient demonstrated that a limited number of antibody variable
region genes encode the autoantibody repertoire, with different genes for pathogenic and non-pathogenic
mAbs. Here, we investigated the feasibility of specific autoantibody targeting in pemphigus. We produced
rabbit anti-idiotypic antibodies against two pathogenic and two non-pathogenic PV mAbs. Antisera inhibited
binding of the immunizing mAb to Dsgs by ELISA as well as pathogenicity against cultured human keratinocytes.
Antisera also inhibited other mAbs using the same variable region heavy chain (VH) genes, despite different
light chains or somatic mutations. Additionally, peptide phage display identified peptide sequences that bound
PV mAbs in a VHspecific manner. To evaluate the therapeutic potential of VH gene-targeted reagents,
preimmune sera and antisera were used to adsorb pathogenic antibodies from PV sera. Pooled antisera
significantly reduced pathogenic activity from the original PV patient’s serum and bound pathogenic antibodies
from two other PV sera, suggesting shared autoantibody VH gene usage among PV patients. Together, these data
suggest novel VH gene-targeted approaches toward PV treatment.
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INTRODUCTION
Pemphigus is an autoimmune blistering disease of the skin
and mucous membranes characterized by antibodies against
the keratinocyte cell surface adhesion proteins desmoglein
(Dsg) 1 and 3 (Stanley, 2003). There are two primary forms of
pemphigus, pemphigus foliaceus (PF) and pemphigus vulgaris
(PV). PF is characterized by autoantibodies against Dsg1,
which cause blistering of the skin, but not mucous
membranes, owing to loss of cell adhesion in the superficial
epidermis. Mucosal PV is characterized by autoantibodies
against Dsg3, which cause suprabasilar blistering of the
mucous membranes. Mucocutaneous PV patients, who
demonstrate both mucous membrane and skin involvement,
usually develop additional autoantibodies against Dsg1. In
both PV and PF, anti-Dsg antibodies are responsible for the
positive direct and indirect immunofluorescence tests that are
the pathognomonic feature of these diseases.
Experiments using passive transfer of autoantibodies to
neonatal mice have demonstrated that the anti-Dsg anti-
bodies in patients’ sera are pathogenic (reviewed previously
by Payne et al., 2004). However, not all anti-Dsg antibodies
cause disease. Epitope mapping studies have shown that the
more pathogenic autoantibodies tend to bind the amino-
terminal extracellular domain of Dsgs that is predicted to
form the trans-adhesive interface between cells (Boggon
et al., 2002), whereas the less or non-pathogenic antibodies
bind more membrane-proximal extracellular domains (Futei
et al., 2000; Sekiguchi et al., 2001; Hacker-Foegen et al.,
2003; Li et al., 2003).
Before the advent of corticosteroids, PV was a uniformly
fatal disease due to severe blistering of the skin and
oropharynx, with resulting malnutrition and sepsis. Currently,
therapy for pemphigus relies on general immunosuppression,
typically with corticosteroids, steroid-sparing agents, and/or
adjunctive treatments such as intravenous immunoglobulin
or plasmapheresis, most of which target the total antibody
pool. Although mortality from pemphigus has decreased due
to these therapies, a significant amount of patient morbidity
and rarely mortality now results from side effects of these
treatments. More specific antibody-targeted therapies for
pemphigus would aim to suppress or eliminate only the
anti-Dsg autoantibodies. The most specific therapy would be
to target only the pathogenic autoantibodies. Antibodies
could be targeted by their idiotype, an approach that has
been previously reported for PF (Alvarado-Flores et al., 2001).
Alternatively, antibodies could be targeted based on their
variable region gene usage, which has shown promise for
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other autoantibody-mediated diseases such as idiopathic
thrombocytopenic purpura (Roark et al., 2002). Either
approach would require direct characterization of the
individual (i.e., monoclonal) antibody populations that cause
disease.
Prior studies using mouse-human heterohybridomas have
isolated pathogenic and non-pathogenic mAbs from PV
patients (Bhol and Ahmed, 2002; Qian et al., 2006; Yeh
et al., 2006). However, heterologous cell fusion techniques
are inefficient in capturing autoantibody repertoires, with cell
lines often losing human chromosomes over time (Siegel,
2001). Anti-Dsg mAbs have also been generated using an
active immune mouse model of PV, in which splenocytes
from a Dsg3-deficient mouse were passively transferred to
Rag2-deficient mice that express Dsg3, resulting in patho-
genic and non-pathogenic anti-Dsg antibodies (Amagai et al.,
2000). Although some of these murine mAbs are pathogenic
against human Dsg3, they are suboptimal for direct thera-
peutic targeting as they are mouse alloantibodies to murine
Dsg3, with unclear clinical relevance to human anti-Dsg
autoantibodies from PV patients.
We recently reported the cloning of pathogenic and non-
pathogenic human PV mAbs by phage display (Payne et al.,
2005). One of the goals of cloning mAbs from pemphigus
patients is to determine if therapy targeted to pathogenic
antibodies is feasible. For such therapy to be practical, PV
patients would have to demonstrate a limited genetic
diversity of anti-Dsg pathogenic antibodies. Such genetic
restriction was suggested by sequence analysis of the initial
PV patient (PV(1)) library (Payne et al., 2005). Reagents could
then be developed to block pathogenic antibodies from
binding Dsg target antigens and causing disease. Ultimately,
these reagents would need to be effective among different
patients. Here, we investigated both anti-idiotypic and VH
gene-targeted approaches to determine the feasibility of
blocking pathogenic antibody populations in PV.
RESULTS
Genetic restriction of PV(1) mAb library
Previously, we reported the cloning of anti-Dsg mAbs from a
patient with active mucocutaneous PV (Payne et al., 2005).
Genetic analysis of 63 sequences from the PV(1) mAb library
demonstrated 43 unique mAbs based on V(D)J gene usage,
heavy- and light- chain combinations, and somatic hypermu-
tation. However, these 43 unique mAbs were encoded by a
total of only seven variable heavy chain (VH) genes. When
these antibodies were further subdivided by antigenic target
and pathogenicity, only one to two VH genes were identified
for each functional category (detailed in Table 1). Each of the
43 unique mAbs used one of 11 different D genes and one of
two different joining heavy chain genes, but these gene usage
patterns did not correlate with antigenic target or pathogeni-
city. Light-chain gene analysis also demonstrated genetic
restriction, with nine different VL genes (Table 2) combining
with three different joining light-chain genes. For anti-
idiotype reagent production, we chose representative patho-
genic and non-pathogenic PV mAbs that were selected
against Dsg3 alone (D3), or both Dsgs 3 and 1 (D31).
ScFv nomenclature has been described previously (Payne
et al., 2005). Briefly, the single-chain variable fragment (scFv)
designation includes the target antigens, (D3) or (D31),
followed by a numeric designation for the heavy and light
chain (i.e., 2/28), which is based on the V(D)J gene usage.
Somatic mutation is indicated by small letter suffix; for
example, (D3)3a/9 and (D3)3c/9 use the same heavy-chain
(‘3’) and light chain (‘9’) variable region genes, but differ
by somatic mutation in the heavy-chain variable region
(‘a’ versus ‘c’).
Production of anti-idiotype antibodies against pathogenic and
non-pathogenic PV mAbs
Recombinant pathogenic (D3)3c/9, (D31)2/28, and non-
pathogenic (D3)1d/2c, (D31)12b/6 scFv PV mAbs were
produced and purified by nickel chelation chromatography
as described previously (Payne et al., 2005). Rabbits were
immunized with scFv preparations by a commercial vendor.
The resulting rabbit antisera were first cleared against an
irrelevant scFv and excess hemagglutinin (HA) peptide,
followed by exhaustive clearing against polyclonal normal
human IgG, in order to eliminate antibodies that reacted
against non-idiotypic determinants.
ScFv antibody fragments express the monovalent antigen-
binding sites of native immunoglobulin molecules. To
evaluate the ability of rabbit antisera to bind PV mAbs in
their native form, scFv were converted to bivalent full-length
IgG1 molecules using the PIGG vector (Rader et al., 2002).
Table 1. VH gene restriction in the PV(1) phage
display library
Antigenic specificity VH genes Pathogenic Non-pathogenic
Dsg 1 2 VH3-8 VH4-b
Dsg 3 3 VH3-07 VH3-30
VH1-e
Dsg 3+Dsg 1 2 VH1-4M28 VH4-04
Total 7 3 4
Table 2. VL gene restriction in the PV(1) phage display
library
Antigenic specificity VL genes Pathogenic Non-pathogenic
Dsg 1 2 VL2-a2 VL3h
Dsg 3 4 VL2-b2
VKIII-L6
VL1-c
VL1-g
Dsg 3+Dsg 1 3 VL3-r VL1-g
VL3-j
Total 9 4 5
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We detected dose-dependent binding of antisera to bivalent
PV IgG by ELISA (Figure 1a). Figure 1a demonstrates that the
antiserum raised against (D31)2/28 (‘Anti-2/28’) also bound
(D31)2/29, an mAb which uses the same heavy chain (VH1-
4M28) but has a different light chain. Anti-2/28 antiserum did
not bind to (D31)12b/6, which uses different heavy- and
light- chain genes. To evaluate for potential crossreactivity of
antisera with different PV IgG, PV IgG were directly absorbed
to ELISA plate wells and incubated with rabbit preimmune
and immune sera. Figure 1b demonstrates that antisera
specifically bound the immunizing mAb, with the exception
of anti-2/28 antiserum, which also bound (D31)2/29. Anti-
serum raised against (D31)12b/6 did not crossreact with
E1M2 IgG (an anti-red blood cell mAb (Chang and Siegel,
1998) produced using the same eukaryotic PIGG expression
system), which uses the same VL gene (VL1-g). These data
indicate that the epitopes recognized by some antisera are
encoded by the heavy chain. Antisera did not recognize the
denatured heavy or light chains of the target IgG by
immunoblot (data not shown), suggesting that a conforma-
tional epitope was recognized.
Anti-Dsg idiotypes correlate with PV mAb VH gene usage
The phage display technique randomly pairs heavy- and
light- chains during PCR construction of the scFv library, and
thus mAbs isolated by phage display may not accurately
reflect heavy and light chain pairings in vivo. If, however, the
idiotypes of PV mAbs are displayed predominantly by the
heavy chain, then development of anti-idiotypic reagents for
pemphigus antibodies could be simplified.
To characterize the specificity of anti-idiotypic antisera,
we tested each antiserum for its ability to inhibit binding of
various PV mAbs to Dsg antigens by ELISA. In initial
experiments, dose–response curves for anti-idiotypic antisera
inhibition were established, using preimmune serum as a
control (Figure S1). Subsequently, ELISA inhibition assays
were performed to evaluate the ability of each antiserum to
inhibit binding of various PV mAbs to Dsg 3 and Dsg1.
Figure 2 summarizes representative inhibition data for all PV
mAb inhibition assays, using equivalent dilutions of anti-
idiotypic antisera (1:20). Incubations in which the antisera
were raised against an mAb using the same VH genes as the
mAb tested by ELISA are highlighted in gray, demonstrating
that antisera specifically inhibited Dsg binding by the original
immunizing mAb, as well as mAbs that used the same VH
genes. For example, the anti-2/28 antiserum inhibited
(D31)2/28 as well as (D31)2/29, an antibody using the same
VH but different VL genes.
Antisera did not inhibit mAbs that used different VH genes.
Notably, the antiserum against (D31)2/28 pathogenic mAb
did not inhibit binding of (D3)3c/9 pathogenic mAb to Dsg3,
indicating that these two pathogenic antibodies do not share
the same idiotype.
Additionally, the presence of somatic mutation did not
appear to affect anti-idiotype antisera inhibition. For exam-
ple, (D3)3c/9 and (D3)3a/9, as well as (D3)1d/2c and (D3)1g/
2e, were similarly inhibited by anti-idiotypic antisera.
One non-pathogenic mAb, (D3)4/30, did not effectively
immunize rabbits and was not substantially inhibited by any
of the other four antisera, which were all produced against
mAbs using different heavy-chain genes. PV(1) serum,
obtained from the patient at the same time the phage display
library was produced, showed 19% inhibition of total Dsg
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Figure 1. Anti-idiotype antisera specifically bind PVmAbs.
(a) Dose-dependent binding of PV mAbs by anti-idiotype antisera.
Recombinant PV monoclonal IgG or monoclonal IgG1 lambda were adsorbed
directly to ELISA plates and incubated with dilutions of anti-2/28 antiserum,
followed by development with HRP-coupled anti-rabbit IgG. (b) Anti-idiotype
antisera binding is specific. Recombinant PV monoclonal IgG or E1M2
negative control IgG (an anti-red blood cell antibody; Chang and Siegel,
1998) were adsorbed directly to ELISA plates and incubated with dilutions of
preimmune sera or anti-idiotype antisera (1:1,000), followed by development
with HRP-coupled anti-rabbit IgG. The bottom row was incubated only with
HRP-coupled anti-human IgG as a control for IgG adsorption to the plate.
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binding when all four antisera were used for inhibition in
ELISA assays.
Taken together, these data suggest that the major idiotypes
of the PV mAbs studied correlate with VH gene usage and are
not significantly altered by somatic mutation or light chain
gene usage, indicating that targeting of either idiotypes or VH
genes may be a viable strategy for therapy.
Anti-idiotype antibodies block pathogenicity of PV mAbs
We next investigated whether the in vitro inhibition of Dsg
binding by ELISA translated into a functional block of
antibody pathogenicity. We have previously shown that
neonatal mouse injection is suboptimal for evaluation of
pathogenicity of PV mAbs, due to differences in the
specificity of mAbs for human versus mouse Dsg substrates
(Payne et al., 2005). Therefore, we evaluated the inhibition of
mAb pathogenicity by a dispase assay using cultured primary
human keratinocytes (Ishii et al., 2005). Pathogenic PV mAbs
(D3)3c/9, (D3)3a/9, (D31)2/28, and (D31)2/29 induced cell
sheet dissociation in cultured human keratinocytes after pre-
incubation with rabbit preimmune serum (top row, Figure 3).
However, after preincubation with VH-specific antisera (anti-
3c/9 antisera in the case of (D3)3c/9 and (D3)3a/9, and anti-
2/28 antisera in the case of (D31)2/28 and (D31)2/29), the
number of cell sheet fragments induced by PV mAbs was
reduced (middle row, Figure 3). Inhibition of cell sheet
fragmentation was not seen after preincubation of PV mAbs
with antisera raised against PV mAbs using different VH genes
(data not shown). Similar to our findings on ELISA, these data
demonstrate that anti-idiotype antisera specifically inhibit the
pathogenicity of PV mAbs on the basis of their VH gene
usage, despite the presence of different light chains or
somatic mutation.
Peptide phage display identifies sequences that bind PV mAbs
according to VH gene usage
Another method that might be used to target antibodies is to
develop small peptides that bind pathogenic antibodies. To
test the feasibility of this approach, we screened linear 12-
mer and disulfide constrained 7-mer peptide phage display
libraries with pathogenic (D31)2/29 PV mAb. Pools of phage-
displayed peptides from the third round of selection demon-
strated specific binding of both (D31)2/28 and (D31)2/29
mAbs, but not the nonpathogenic (D31)12b/6 mAb or an
IgG1 lambda mAb (Sigma, St Louis, MO) by ELISA (Figure
S2), suggesting heavy-chain specificity of peptide binding.
Preparations of individual binding phage clones were isolated
and their displayed peptide amino-acid sequences were
deduced by sequencing phage DNA (Figure 4). Interestingly,
a consensus peptide sequence was identified. Neither the
consensus sequence nor the individual peptide sequences
aligned with any linear sequence in human desmosomal
cadherins. Additionally, monoclonal peptide phage did not
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Figure 2. Antisera inhibition of PV antibody binding to Dsg3/Dsg1 by ELISA. Pathogenic mAbs are indicated by an asterisk. ND, not determined.
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Figure 3. Anti-idiotypic antisera inhibit pathogenicity of PV mAbs according
to VH gene usage. PV mAbs were preincubated with cleared rabbit
preimmune sera or antisera before incubation with primary human epidermal
keratinocytes. ETA was added to (D3) antibody incubations at a final
concentration of 1 mg/ml in order to inactivate Dsg1. Intact cell sheets were
released from the cell culture plate by treatment with dispase and subjected
to mechanical shear stress. The ability of rabbit antisera to inhibit cell sheet
dissociation by PV mAbs was quantified by counting the resulting number
of cell sheet fragments, shown as a mean (SD).
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demonstrate direct binding to human Dsg3 by ELISA (data not
shown), suggesting that these sequences do not mimic linear
or conformational epitopes of Dsgs that may be involved in
homo- or hetero-dimerization.
VH-specific binding of individual phage-displayed pep-
tides to PV mAbs was confirmed by ELISA. PV mAbs were
immobilized on microplate wells and incubated with peptide
phage. Peptide phage demonstrated selective binding of
(D31)2/28 and (D31)2/29 mAbs, but not other PV mAbs using
different VH genes (Figure 5). Control peptide phage
displaying a non-consensus sequence (DLNYFTLSSKRE), as
well as wild-type peptide phage displaying pIII coat protein
unligated to any additional peptide sequence (data not
shown), did not show significant binding to any PV mAb.
Select peptide phage were tested for their ability to inhibit
binding of PV mAbs to Dsg substrates by ELISA (Figure 6).
Control phage displaying the non-consensus sequence did
not demonstrate significant inhibition of PV mAb binding.
P14 peptide phage also did not inhibit binding of any PV
mAb. However, P4 and P7 peptide phage inhibited binding
of (D31)2/29 by 78 and 83%, respectively, indicating that
these peptides are anti-idiotypic reagents. Again, inhibition
was dose dependent (data not shown). Although P4 and P7
peptide phage bound to (D31)2/28 mAb, they did not inhibit
its binding to Dsg3.
Thus, as with the anti-idiotypic antibodies, specific
binding of peptide phage to PV mAbs was mainly determined
by VH gene usage. However, the binding of peptides to PV
mAbs did not correlate with functional inhibition of mAb
binding to Dsg3, indicating that the idiotype of PV mAbs may
be modified by the light chain.
Anti-idiotypic antisera deplete pathogenic activity from PV(1)
serum
Although the ELISA inhibition data (Figure 2) suggested that
the pooled antisera did not inhibit the majority of total anti-
Dsg binding in PV(1) serum, many anti-Dsg antibodies do not
cause disease. We therefore tested whether the mAbs
targeted by the antisera represented the critical pathogenic
antibody populations using the keratinocyte dissociation
assay. Collectively, the previous data demonstrate that both
anti-idiotypic antibodies and small molecule reagents can
specifically bind PV mAbs based on their heavy chain gene
usage. Therefore, instead of targeting antibodies based on
their idiotype, which may be a more restrictive functional
definition and influenced by the light chain, we investigated a
more general antibody targeting strategy based on antibody
VH gene usage.
Rabbit preimmune and immune IgG were cleared only
against an unrelated scFv (AM3-13, an anti-platelet antibody
encoded by VH1-24 and VKI-O12/O2 genes) and excess HA
peptide (and not against normal human IgG, which could
clear antibodies that react against VH framework regions of
the antibody). Antisera against non-pathogenic PV mAbs
were included in case these antibodies contributed to
pathophysiology when used in combination. Preimmune
and immune IgG were immobilized on a solid phase matrix
and used to determine whether pathogenic antibodies could
be adsorbed from various PV sera. PV(1) serum is pathogenic
in the dispase assay (Figure 7o). After adsorption with rabbit
pre-immune IgG, PV(1) serum retained pathogenic activity
against cultured human keratinocytes (Figure 7a). However,
after adsorption with the four pooled PV antisera IgG,
pathogenic activity of PV(1) serum was substantially reduced
(Figure 7b). Acid elution of adsorbed proteins followed by
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Figure 4. Peptide sequences identified by peptide phage display screening
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was developed with HRP-coupled anti-human IgG.
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neutralization demonstrated that pathogenic antibodies did
not bind to the rabbit pre-immune column (Figure 7c). In
contrast, PV(1) serum adsorbed by the four pooled PV
antisera showed increased cell sheet fragmentation activity
in the eluate, suggesting specific binding of pathogenic
antibodies (Figure 7d). Two other PV patient sera, PV3210
and PV3274, did not show significant depletion of patho-
genic activity by the four-pooled antisera (Figure 7, compare
e–f, and i–j). However, pathogenic antibodies were eluted
from both PV sera after adsorption with the four pooled
antisera (Figure 7h and l), but not after adsorption with pre-
immune IgG (Figure 7g and k). Exfoliative toxin A (ETA)
(Figure 7m) or PF serum (Figure 7n), which only recognize
Dsg1, do not demonstrate significant pathogenicity in the
keratinocyte dissociation assay, which requires inactivation
of both Dsg1 and Dsg3. These data suggest that the four VH
gene sets identified from the PV(1) patient library deplete a
substantial proportion of the pathogenic activity from the
patient’s own serum. In addition, pathogenic antibodies using
these VH genes are shared among different PV patients,
although additional pathogenic autoantibody VH genes are
likely present in these other patients.
DISCUSSION
Autoantibody gene restriction in pemphigus
Genetic analysis of cloned antibodies from the PV(1) library
demonstrated a restriction of autoantibody VH gene usage,
with different VH gene usage by pathogenic and non-
pathogenic antibodies (Table 1). Additionally, PV mAb VH
gene usage appeared to correlate with antibody function,
with respect to both Dsg antigen binding and pathogenicity.
Genetic restriction in the light chain repertoire was also
observed (Table 2), suggesting functional importance (dis-
cussed below). The identification of limited genetic diversity
in PV mAbs suggested that we may be able to improve the
specificity and potentially the safety of pemphigus therapies
by targeting only the anti-Dsg antibodies, as opposed to
generally suppressing the immune system. The studies
presented here aimed to explore the feasibility of such
approaches.
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Figure 7. Pooled antisera depletes pathogenic activity from PV(1) serum and binds pathogenic antibodies from different PV patients’ sera. Preimmune
IgG and pooled antisera IgG were coupled to solid phase matrix and used to deplete various PV patients’ sera, including PV(1), the patient from whom
the PV(1) phage display library was produced. Owing to the low anti-Dsg1 titer of PV3210 and PV3274 sera, ETA was added to incubations using these sera.
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Restricted patterns of heavy- and light- chain gene usage
have been described for a number of autoimmune and
naturally occurring immune responses, including idiopathic
thrombocytopenic purpura, systemic lupus erythematosus,
rheumatoid arthritis, cold agglutinins, HIV, and Haemophilus
influenzae type b infection, among others (Adderson et al.,
1991; Silberstein et al., 1991; Newkirk et al., 1993; Ditzel
et al., 1996; Roben et al., 1996; Roark et al., 2002). The
presence of antibody gene restriction in autoimmune and
immune states is not surprising, as a limited number of
antibody variable region genes would be expected to confer
the ability to bind a specified target antigen. For example,
antibodies that bind the human red cell Rh(D) antigen use
VH gene segments that encode polypeptides with higher
isoelectric points, which has been suggested to facilitate
binding of epitopes in the negatively charged red cell
membrane (Boucher et al., 1997). In the case of PV and PF,
Dsg antigens are largely conserved among patients, with the
possible exception of case reports demonstrating Dsg3 and
Dsg1 haplotypes, respectively, that are associated with
disease (Martel et al., 2001; Capon et al., 2006). Owing to
the conservation of Dsg antigens among patients, it is logical
that autoantibody VH gene usage may be restricted and
shared among patients and thus may serve as a therapeutic
target.
It is likely that the phage display technique does not
capture all of a patient’s anti-Dsg mAbs, owing to potential
bias that may be introduced by the selection process and how
well individual phage clones grow in culture. This was
supported by our ELISA inhibition assays (Figure 2), which
demonstrated that all four antisera inhibited only 19% of total
PV(1) serum Dsg3 binding. A similar percent inhibition of
PV(1) binding was observed when all four antisera were used
to deplete PV(1) sera before the Dsg3 ELISA binding assay
(data not shown), indicating that the percent inhibition
observed in competitive binding assays was not secondary
to relative affinities of PV serum IgG for Dsg versus antisera
substrates. One non-pathogenic mAb, (D3)4/30, was not
specifically targeted by the antisera and presumably con-
tributed to residual Dsg3 binding by the depleted serum. Of
note, the 19% inhibition observed with all four antisera was
lower than the total inhibition expected when each of the
four antisera was used individually to inhibit PV(1) binding
(cumulative total inhibition approximately 36%). This finding
may be explained by cooperative binding of PV autoanti-
bodies to Dsg (Tsunoda et al., 2006; ASP, unpublished data).
Although the mAbs cloned from the PV(1) patient were
likely not inclusive of all serum anti-Dsg antibodies, our data
suggest that we have identified critical pathogenic antibody
populations, as targeted VH gene depletion of PV(1) serum
with the four antisera resulted in a marked reduction in PV(1)
serum pathogenicity (Figure 7). These findings argue against
the possibility that the genetic restriction observed was solely
owing to inefficient isolation of disease-relevant antibody
clones from the patient library. These data suggest that for an
individual patient, we have identified restricted populations
of anti-Dsg mAbs by phage display, generated VH gene-
targeted reagents that specifically bind and inhibit these anti-
Dsg mAb populations, and used these reagents to deplete a
majority of PV(1) serum pathogenic activity.
Shared VH gene usage among pemphigus patients
The feasibility of more generally applicable VH gene-targeted
therapies for PV relies on the presence of shared pathogenic
antibodies among patients. The paradigm of VH gene
restriction in autoimmune diseases suggests that a limited
number of VH genes may be able to cause disease. Our data
demonstrate that antibody function and the binding and
inhibition of anti-idiotypic reagents correlate with VH gene
usage (Table 1 and Figures 1 and 2). Thus, instead of
screening PV patients for shared antibody idiotypes, which
may be more difficult to detect owing to their presumed low
level of representation in the total autoantibody repertoire,
we screened two independent PV patients for pathogenic
antibodies that may use the same VH genes. Because recent
experiments in mice have suggested that combinations of
non-pathogenic PV mAbs may result in pathogenic activity
(Kawasaki et al., 2006), we used all four antisera for antibody
adsorption.
The four antisera against VH genes identified from the
PV(1) patient adsorbed pathogenic antibodies from two
different PV patients (Figure 7h and l), suggesting that some
or all of these VH genes are used by pathogenic antibodies in
these two patients. However, the inability to deplete
significant pathogenic activity from the two patient sera
(Figure 7f and j) suggests either a significantly higher titer of
antibodies using the VH genes in these sera, or more likely,
additional VH gene usage by pathogenic antibodies in these
two patients. We have demonstrated that the antisera are
specific for certain VH genes (Figures 1 and 2), thus making
the possibility of crossreactive binding of antisera to
unrelated PV mAbs unlikely. Ultimately, VH gene analysis
of more PV patient autoimmune repertoires may identify
additional disease-associated VH genes for targeting.
Anti-idiotypic antibodies bind and inhibit PV mAbs according to
VH gene usage
With the phage display technique, heavy and light chains are
randomly paired during PCR construction. However, light-
chain shuffling experiments have demonstrated that repro-
ducible heavy- and light- chain combinations are isolated
after (but not before) phage library selection (Roben et al.,
1996; Roark et al., 2002). These findings indicate that a
preferential association of heavy and light chains is detected
when the functional constraint of antigen binding is imposed.
Thus, the heavy- and light- chain combinations in mAbs
isolated by phage display may in fact represent biologically
relevant pairings.
Crystal structures of antibody variable regions have shown
that the antigen binding pocket is formed at the interface of
the VH and VL genes (Rose et al., 1993; Ay et al., 2000).
These and other reports have demonstrated that the VH gene
encodes the majority of the antigenic binding determinants,
primarily through the CDR3 (Arevalo et al., 1993; Ban et al.,
1995; Graille et al., 2000). Other studies have shown that the
CDR3 of the heavy chain is sufficient for antigen recognition
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(Barbas et al., 1995), even in the absence of the light chain
(Bourgeois et al., 1998; Zwick et al., 2004). The presence of
different light chains has been proposed to influence antibody
affinity in addition to epitope specificity (Ibrahim et al., 1995;
Ohlin et al., 1996; Hoet et al., 1999). Consistent with this,
our peptide phage inhibition data indicate the relevance of
the light chain for some antibody idiotypes, as P4 and P7
peptide phage bound both (D31)2/28 and (D31)2/29 patho-
genic antibodies but only inhibited (D31)2/29 from binding
to Dsg3.
Despite fine differences in anti-idiotypic inhibition of PV
mAbs by monoclonal peptide phage, our data demonstrate
that the binding of anti-idiotypic antibodies and peptide
reagents to PV mAbs correlates with VH gene usage (Figures
1, 2, and 5). Neither different light chains nor somatic
mutation of the variable region outside the CDR3 affected the
binding or inhibition of anti-idiotypic antisera (Figures 1–3).
These data suggest that PV mAb VH genes identified by phage
display represent feasible targets for therapy.
Identification of a peptide consensus sequence for PV mAb
binding
Using peptide phage display, we have identified linear
peptide sequences that specifically bind pathogenic PV mAbs
(Figures 4 and 5). These reagents, similar to the anti-idiotype
antisera, are VH-specific in their binding of PV mAbs.
Interestingly, the consensus peptide sequence includes a
tryptophan residue (Figure 4). Membrane distal tryptophan
residues form a critical part of the trans-adhesive interface
between cells for the classical cadherins, whose extracellular
domain structures have been determined (Shapiro et al.,
1995; Nagar et al., 1996; Boggon et al., 2002). However, the
consensus sequence identified does not correlate with any
linear sequence in human Dsgs 1–4 or human desmocollins
1–3. Additionally, peptide phage displaying the consensus
sequence did not demonstrate specific binding directly to
Dsg3 by ELISA, and injection of peptides into normal human
skin did not result in any tissue pathology (data not shown).
These data suggest that the peptide sequences identified do
not mimic the desmosomal cadherin adhesive interface but
instead encode sequences for direct binding of specific VH
genes. Such reagents could be chemically modified to
optimize pathogenic antibody adsorption from PV sera
(discussed below).
Therapeutic implications
Recently, rituximab, a monoclonal antibody against the B-
cell surface antigen CD20, has shown promise for the
treatment of autoimmune diseases including pemphigus
(Espana et al., 2004; Arin et al., 2005; Ahmed et al., 2006).
The exact mechanism of action is unclear, as less than 20% of
circulating plasma cells express CD20, but rituximab is
thought to deplete B-cell precursors that may ultimately
give rise to autoantibody-secreting plasma cells. Never-
theless, the anecdotal success of rituximab underscores the
importance of the humoral immune response for perpetuating
disease. As an alternative to broadly targeting anti-
body-producing cells, treatments could be aimed directly
against the disease-causing anti-Dsg antibodies or the B cells
that produce them.
The cloning of human PV mAbs may identify novel
strategies for such direct antibody targeting. Our current
data suggest that treatments could be designed on the basis
of autoantibody VH gene usage. In addition, the identification
of peptides that specifically bind PV mAbs (Figure 5) provides
proof of principle that small molecule reagents can also
be identified that can discriminate among PV mAbs based
on their VH gene usage. These small molecule reagents are
more practical than rabbit anti-idiotypic antibodies for the
development of therapeutic intervention strategies, although
the latter approach is also amenable to humanization
strategies through phage display (Steinberger et al., 2000).
Such antibody-targeted reagents could be coupled to
columns as an adjunct for plasmapheresis to improve the
efficiency of pathogenic antibody removal from patients’
sera. Alternatively, antibody-specific reagents could be
linked to B cell superantigens as a method of VH-targeted
B-cell deletion, similar to what has previously been
described for the selective deletion of VH3 family genes by
Staphylococcus aureus protein A (Goodyear and
Silverman, 2003, 2004). Although beyond the scope of
the current study, these novel approaches to antibody-
targeted therapy offer hope for potentially safer and more
effective treatments for pemphigus. In addition, the VH gene-
targeting approach described may have implications for
the treatment of other genetically restricted antibody-
mediated diseases.
MATERIALS AND METHODS
All experiments were conducted in accordance with the Declaration
of Helsinki Principles for Human Tissue Research and were
approved by the Necessary Regulatory Boards of the University of
Pennsylvania.
Production of anti-idiotype antisera
ScFv mAbs were produced in the Top10F’ strain of E. coli
(Invitrogen, Carlsbad, CA) and purified by nickel chelation affinity
chromatography as described previously (Payne et al., 2005). Rabbit
antisera were commercially produced by Cocalico Biologicals Inc.,
according to the vendor’s standard protein immunization protocol.
Rabbit antisera were first cleared against an irrelevant human
scFv, AM3-13 (encoded by VH1-24 and VKI-O12/O2 genes), along
with excess HA peptide. To produce the column, 520 mg of AM3-13
and 60 mg of HA peptide (Sigma, St Louis, MO) were coupled to
500ml of Affigel 15 matrix (BioRad, Hercules, CA) according to the
manufacturer’s instructions. Rabbit antiserum (500 ml) was incubated
with the coupled beads by end-over-end rotation overnight at 41C.
The flow through the column was collected and combined with the
flow through after washing with one bed volume of PBS, pH 7.4.
Clearing was evaluated by testing the antisera for depletion of anti-
HA activity by ELISA.
To produce an affinity column comprising normal human IgG,
10 mg of human IgG (Sigma) was coupled to 1 ml of Affigel 10 matrix
(BioRad) according to the manufacturer’s instructions. 1 ml of rabbit
antiserum was incubated with the human IgG affinity column by
end-over-end rotation for 8–16 hours at 41C and the flow through
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from the column was collected and combined with the flow through
after washing with one bed volume of PBS, pH 7.4. The column was
then washed with an additional 10 bed volumes of PBS and bound
IgG was eluted with six bed volumes of 100 mM glycine, (pH 2.5).
The elution fractions were neutralized with 1/10 volume of 1 M Tris,
(pH 7.5), and the column was neutralized by washing with 20 bed
volumes of PBS, (pH 7.4). Binding and elution steps were repeated
for 3–8 times, until the A280 of the eluate from the column
stabilized. The flow through fractions (comprising the cleared
antisera) were pooled and concentrated by Centricon YM-10
ultrafiltration (Millipore, Billerica, MA).
To produce rabbit anti-idiotype columns, rabbit IgG was
purified from preimmune and immune sera by protein A adsorption
and elution with acid glycine. The eluate was dialyzed against PBS,
(pH 7.4). Purified rabbit preimmune or antisera IgG (2.5 mg) was
coupled to 500 ml of Affigel 10 matrix (BioRad) as above. PV sera
(250ml) was adsorbed with the rabbit IgG affinity column overnight
at 41C and the flow through and eluate were collected as described
above.
Production of bivalent IgG1 from monovalent scFv mAbs
The eukaryotic PIGG expression vector was provided by Carlos
Barbas (Scripps Research Institute). Primers used to subclone scFv
mAbs into the PIGG vector appear in Table S1. PV mAbs, contained
in the scFv phagemid expression vector pComb3X, were used as the
PCR template for the antibody variable region amplifications. E1M2
Fab in the phagemid expression vector pComb3H (Roark et al.,
2002) was used as the PCR template for the constant region of the
lambda light chain (CL).
The variable region of the heavy chain (VH) was amplified with a
50 primer based on the sequence of PIGG-A, which introduces an
SacI cloning site (Rader et al., 2002), along with 30 primer
HSCG1234B (Barbas et al., 2001), which includes the endogenous
ApaI restriction sequence at the start of the IgG1 CH1 region. The
PCR reaction was purified using the Qiaquick PCR purification kit
(Qiagen, Valencia, CA) and digested with SacI and ApaI (New
England BioLabs, Ipswich, MA). The SacI–ApaI fragment was purified
by agarose gel electrophoresis using the Qiaquick Gel Extraction Kit
(Qiagen) and was subcloned into the SacI–ApaI site in the PIGG
vector.
The variable region of the light chain (VL) was amplified with a 5
0
primer based on the sequence of PIGG-C (Rader et al., 2002), which
introduces a HindIII cloning site and abolishes the internal SacI
cloning site, which would otherwise have been amplified from the
pComb3X vector. The 30 primer for the VL region hybridizes in
reverse orientation to the 30 end of the VL sequence. The CL region
was amplified from E1M2 Fab using 50 primer HLC-F (Barbas et al.,
2001) and 30 Lead B reverse primer (Barbas et al., 2001). The VL and
CL PCR fragments were purified by agarose gel electrophoresis as
above and quantitated by relative ethidium bromide fluorescence.
The VL–CL region was produced by overlap PCR, using approxi-
mately 50 ng each of the VL and CL PCR fragments as the template,
and the 50 light chain and 30 lead B reverse primers. The VL–CL
overlap PCR reaction was PCR purified, digested with HindIII and
XbaI (New England BioLabs), and purified by agarose gel electro-
phoresis before subcloning in the HindIII–XbaI site of the PIGG
vector. All recombinant constructs were verified by automated
sequencing.
PIGG vector expression
Endo-free plasmid maxipreps (Qiagen) of recombinant PIGG vectors
were prepared for eukaryotic cell transfection into 293T cells. PIGG
vector transfection was performed using jetPEI reagent (ISC Bio-
Express, Kaysville, UT) according to the standard protocol, using five
10 cm cell culture plates at approximately 90% cell density and
DMEM plus 10% ultralow IgG fetal bovine serum (Gibco/Invitrogen,
Carlsbad, CA) as the harvest media. Expressed antibody was
harvested from the cell culture supernatant at 3 days and again at
6 days. Non-adherent cells were removed from the supernatant by
centrifugation, and the media was neutralized by the addition of
1/100 volume 1 M Tris pH 7.5. IgG was purified from the culture
supernatant by rotation with protein A agarose beads (Invitrogen) for
2 hours at room temperature. The beads were transferred to a
disposable chromatography column (BioRad), washed with 20
column volumes of PBS, and eluted with 6 column volumes of
100 mM glycine (pH 3). Eluted fractions were neutralized with 1/10
volume 1 M Tris pH 7.5, and the approximate IgG concentration was
estimated by absorbance at 280 nm using an extinction coefficient of
1.43. Samples were dialyzed into PBS (pH 7.4) and concentrated to
approximately 1mg/ml using Centricon YM-3 spin columns (Milli-
pore, Billerica, MA). Antibody concentration was confirmed by non-
reducing SDS-PAGE followed by Coomassie staining, using a known
amount of monoclonal lambda IgG1 (Sigma) as a concentration
standard for reference. Antibody binding to Dsg was confirmed by
ELISA (Rhigene/MBL, Woburn, MA) according to the manufacturer’s
protocols.
Peptide phage display and techniques
PhD-12 and PhD-C7C peptide phage display libraries (New England
BioLabs) were screened with PV IgG according to the manufacturer’s
instructions, alternating between protein A and protein G magnetic
beads (New England BioLabs) for antibody capture. Phage clones
were isolated from round 3 of screening for sequencing according to
the manufacturer’s protocols. Unique clones were subsequently
characterized by ELISA binding and inhibition assays.
ELISA binding and inhibition assays
For anti-idiotype antiserum binding assays, PV monoclonal IgG were
adsorbed directly to ELISA plates at a concentration of 10 mg/ml in
PBS overnight at 41C. The antigen was discarded, and the plate was
blocked for 1 hour at 371C in blocking buffer (0.1 M NaHCO3, pH
8.6, 5 mg/ml BSA, 0.02% NaN3). After blocking, the plate was
washed with Tris-buffered saline (TBS) containing 0.1% Tween-20.
For antisera evaluation, cleared rabbit pre-immune and immune sera
were incubated at a dilution of 1:1000 (or varying dilutions) on each
well and detected with horseradish peroxidase (HRP)-conjugated
goat anti-rabbit antibodies (Dako, Carpinteria, CA), which demons-
trate minimal crossreactivity with human IgG. As a control for mAb
adsorption to microplate wells, HRP-conjugated anti-human IgG
(Research Diagnostics Inc., Concord, MA) was also reacted with
wells. ABTS (2,20-Azino-di[3-ethylbenzthiazoline-sulfonate], Roche
Applied Science, Indianapolis, IN) was used as the substrate for
ELISA reactions.
For peptide phage binding assays, 0.5 mg of rabbit anti-human Fc
was adsorbed to ELISA plates overnight at 41C in 0.1 M NaHCO3 (pH
9.6). The antigen was discarded, and the plate was blocked as
above. Wells were subsequently incubated with 0.5 mg of various PV
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mAbs in TBS-0.5% Tween-20 for 2 hours at 371C. After washing with
TBS-0.5% Tween-20, 109 PFU of monoclonal peptide phage in TBS-
0.5% Tween-20 were incubated in each well for 1 hour at room
temperature, followed by HRP-conjugated anti-M13 secondary
antibody (Amersham Biosciences/GE Healthcare, Piscataway, NJ)
in blocking buffer and development with ABTS substrate. As a
control to evaluate PV mAb adsorption to microplate wells, 50 ng of
PV mAbs was added to the rabbit anti-human Fc-coated wells, and
then detected with HRP-conjugated anti-human IgG.
For ELISA inhibition assays, anti-idiotypic reagents were pre-
incubated with PV mAbs for 1 hour at 371C before incubation on
Dsg3 or Dsg1 ELISA plates (Rhigene/MBL, Woburn, MA), which
were otherwise processed according to the manufacturer’s instruc-
tions. Anti-idiotypic antisera were effective and dose responsive at
dilutions ranging from 1:3 to 1:6,400, whereas peptide phage were
used in inhibition assays from 108 to 1010 PFU/well. PV scFv
binding, detected with HRP-conjugated anti-HA secondary antibody
(Roche Applied Science), was titrated to a final OD450 reading of
0.4–1.0, which was within the linear range of detection.
Keratinocyte dissociation assay
The keratinocyte dissociation assay was performed as previously
described (Payne et al., 2005), using either PV scFv at 5 mg/ml or PV
sera at dilutions of 1:5–1:7.5 in 500 ml total volume defined
keratinocyte-serum free media (Gibco/Invitrogen). For antibodies
that only recognize Dsg3, 1 mg/ml ETA was added to wells for the
last 2 hours. For antisera depletion assays, 200ml of PV sera
flow through (representing a volume of 100ml sera, combined
with the first 1-volume fraction of the PBS wash) was incubated
with cells in a total volume of 500 ml, with or without ETA treatment.
Dissociation assays used the total eluate from the antisera columns,
concentrated to a volume of 100 ml (representing a starting volume of
250ml sera).
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